6J7W | pdb_00006j7w

Crystal Structure of Human BCMA in complex with UniAb(TM) VH


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.60 Å
  • R-Value Free: 
    0.271 (Depositor), 0.273 (DCC) 
  • R-Value Work: 
    0.208 (Depositor), 0.213 (DCC) 
  • R-Value Observed: 
    0.212 (Depositor) 

Starting Models: experimental
View more details

wwPDB Validation 3D Report Full Report

Validation slider image for 6J7W

This is version 1.2 of the entry. See complete history

Literature

Multispecific Antibody Development Platform Based on Human Heavy Chain Antibodies

Clarke, S.C.Ma, B.Trinklein, N.D.Schellenberger, U.Osborn, M.J.Ouisse, L.H.Boudreau, A.Davison, L.M.Harris, K.E.Ugamraj, H.S.Balasubramani, A.Dang, K.H.Jorgensen, B.Ogana, H.A.N.Pham, D.T.Pratap, P.P.Sankaran, P.Anegon, I.van Schooten, W.C.Bruggemann, M.Buelow, R.Force Aldred, S.

(2018) Front Immunol 9: 3037-3037

  • DOI: https://doi.org/10.3389/fimmu.2018.03037
  • Primary Citation Related Structures: 
    6J7W

  • PubMed Abstract: 

    Heavy chain-only antibodies (HCAbs) do not associate with light chains and their V H regions are functional as single domains, forming the smallest active antibody fragment. These V H regions are ideal building blocks for a variety of antibody-based biologics because they tolerate fusion to other molecules and may also be attached in series to construct multispecific antibodies without the need for protein engineering to ensure proper heavy and light chain pairing. Production of human HCAbs has been impeded by the fact that natural human V H regions require light chain association and display poor biophysical characteristics when expressed in the absence of light chains. Here, we present an innovative platform for the rapid development of diverse sets of human HCAbs that have been selected in vivo . Our unique approach combines antibody repertoire analysis with immunization of transgenic rats, called UniRats, that produce chimeric HCAbs with fully human V H domains in response to an antigen challenge. UniRats express HCAbs from large transgenic loci representing the entire productive human heavy chain V(D)J repertoire, mount robust immune responses to a wide array of antigens, exhibit diverse V gene usage and generate large panels of stable, high affinity, antigen-specific molecules.


  • Organizational Affiliation
    • Teneobio, Inc., Menlo Park, CA, United States.

Macromolecule Content 

  • Total Structure Weight: 33.89 kDa 
  • Atom Count: 2,345 
  • Modeled Residue Count: 311 
  • Deposited Residue Count: 314 
  • Unique protein chains: 2

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
UniAbA,
C [auth B]
118Homo sapiensMutation(s): 0 
Find similar proteins by:|  3D Structure
Entity ID: 2
MoleculeChains  Sequence LengthOrganismDetailsImage
Tumor necrosis factor receptor superfamily member 17B [auth C],
D
39Homo sapiensMutation(s): 0 
Gene Names: BCMA
UniProt & NIH Common Fund Data Resources
Find proteins for Q02223 (Homo sapiens)
Explore Q02223 
Go to UniProtKB:  Q02223
PHAROS:  Q02223
GTEx:  ENSG00000048462 
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ02223
Sequence Annotations
Expand
Reference Sequence

Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.60 Å
  • R-Value Free:  0.271 (Depositor), 0.273 (DCC) 
  • R-Value Work:  0.208 (Depositor), 0.213 (DCC) 
  • R-Value Observed: 0.212 (Depositor) 
Space Group: C 2 2 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 65.392α = 90
b = 73.806β = 90
c = 133.491γ = 90
Software Package:
Software NamePurpose
REFMACrefinement
XDSdata reduction
pointlessdata scaling
PHASERphasing

Structure Validation

View Full Validation Report



Entry History 

Revision History  (Full details and data files)

  • Version 1.0: 2019-02-06
    Type: Initial release
  • Version 1.1: 2023-11-22
    Changes: Data collection, Database references, Refinement description
  • Version 1.2: 2024-11-13
    Changes: Structure summary